Age and TP53 mutation frequency in childhood malignant gliomas: Results in a multi-institutional cohort

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7404-7407

  Pollack, Ian F ^a,d   Finkelstein, Sydney D ^a   Burnham, Judith ^a   Holmes, Emiko J ^d   Hamilton, Ronald L ^a   Yates, Allan J ^b   Finlay, Jonathan L ^c   Sposto, Richard ^e  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GROWTH; CARCINOGENESIS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; GENE MUTATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MUTATION RATE; NUCLEOTIDE SEQUENCE; ONSET AGE; PRIORITY JOURNAL;

EID: 0035887141     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Current concepts: Brain tumors in children
2. Incidence of malignant tumors in U.S. children
3. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome
4. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults
5. Long-term survival in patients with glioblastoma multiforme
6. Long-term survival in patients with malignant astrocytoma
7. Ten-year survival among patients with supratentorial astrocytoma grade III and IV
8. High-grade astrocytomas in children: Radiologically complete resection is associated with an excellent long-term prognosis
9. A molecular genetic model of astrocytoma histopathology
10. INK4 or retinoblastoma protein (pRb) or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines
11. Subsets of glioblastoma multiforme defined by molecular genetic analysis
12. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors
13. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas
14. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
15. 1-S transition control gene abnormalities
16. Clonal genomic alterations in glioma malignancy stages
17. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades
18. Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme
19. Chromosome 10 deletion mapping in human gliomas: A common deletion region in 10q25
20. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas
21. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
22. Progression as exemplified by human astrocytic tumors
23. Epidermal growth factor receptor (EGFR) expression in high-grade non-bruinstem gliomas of childhood
24. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood
25. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations
26. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas
27. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas
28. Randomized Phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen
29. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: Results of a randomized trial. A report from the Children's Cancer Study Group
30. Eight drugs in one day chemotherapy for brain tumors: Experience in 107 children and rationale for preradiation chemotherapy
31. Histological typing of tumours of the central nervous system
32. p53 mutation and loss of heterozygosity on chromosome 17 and 10 during astrocytoma progression
33. p53 mutations in human cancers
34. K-ras-2 and p53 genotyping of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses
35. Whole genome amplification and molecular genetic analysis of DNA from paraffin-embedded prostate adenocarcinoma tumor tissue
36. Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type
37. The lack of a role for p53 in astrocytomas in pediatric patients
38. Alterations of the TP53 gene in human gliomas
39. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas
40. Apoptosis: Its significance in cancer and cancer therapy
41. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
42. Cancer therapy meets p53
43. p53 status and the efficacy of cancer therapy in vivo
44. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer
45. Accumulation of nuclear p53 and tumor progression in bladder cancer
46. Clinical implications of the p53 tumor-suppressor gene
47. p53 point mutation and survival in colorectal cancer patients
48. Adenovirus-mediated p53 gene therapy for human gliomas
49. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line
50. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
51. Survival of infants with malignant astrocytomas: A report from the Children's Cancer Group
52. Treatment of infants with malignant gliomas: The Pediatric Oncology Group experience
53. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors